Overview

Neoadjuvant Herceptin in Patients With Breast Cancer

Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Breast Care Center
Mothaffar Rimawi
Collaborator:
Genentech, Inc.
Treatments:
Trastuzumab